Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors
Launched by GENENTECH, INC. · Jan 27, 2014
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Histologically or cytologically confirmed solid tumor that is relapsed/refractory to standard therapies or for which no approved or curative therapy exists
- • Age \> or = 18
- • Eastern Cooperative Oncology Group (ECOG) performance status \< 2
- • Life expectancy \> or = 12 weeks
- • Adequate hematologic and organ function before initiation of GDC-0919
- • For some patients only: Accessible lesions amenable to paired fresh tumor biopsies
- Exclusion Criteria:
- • Some prior cancer immunotherapies
- • Untreated brain metastases
- • Active or history of autoimmune disease
About Genentech, Inc.
Genentech, Inc. is a leading biotechnology company and a member of the Roche Group, dedicated to transforming the lives of patients with serious medical conditions through innovative therapies. Established in 1976, Genentech is recognized for its pioneering research in biologics and for developing groundbreaking treatments in areas such as oncology, immunology, and neuroscience. With a commitment to scientific excellence and patient-centered care, the company leverages cutting-edge technology and collaborative partnerships to advance drug discovery and development. Genentech's robust pipeline and focus on personalized medicine underscore its mission to address unmet medical needs and improve health outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Augusta, Georgia, United States
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials